SCIENTIFIC  PROGRAM Thursday, November the 7th, 2019
12:00 - 13:00	Registration Opening Ceremony
13:00 - 13:15	Opening Ceremony
13:20 - 13:30	Tomb of Sarteano: the first GO painting in history
	Lelio Baldeschi (Brussels), Maurizio Martinelli (Firenze)
13:30 - 13:50	Mark Prummel memorial lecture
	Chairperson: Claudio Marcocci (Pisa)
	EUGOGO achievements over 20 years - Wilmar Wiersinga (Amsterdam)
13:55 - 15:35	Symposium 1: the lmmunopathogenesis of GO in 2019
	Chairpersons: Paul Banga (London), Marvin Gershengorn (Bethesda)
13:55 - 14:15	Genetics and epigenetics of GO - Simon Pearce (Newcastle upon Tyne)
14:15 - 14:35	Role of fibrocytes in GO - Terry Smith (Ann Arbor)
14:35 - 14:55	Overview of the immune response in GO - Wilfern A.  Dik (Amsterdam)
14:55 - 15:15	The microbioma in Graves' disease and GO - Marian Ludgate (Cardiff)
15:15 - 15:35	Graves' disease and GO following immune reconstitution Ilaria Muller (Cardiff)
15:40 - 16:40	Oral Presentations 1
	Chairpersons: Nicola Curro (Milan),  Michele Marino (Pisa)
16:40 - 17:00	Coffee Break
17:00 - 18:40	Symposium 2: diagnostic issues on GO phenotypes
	Chairpersons: Chistoph Hintschich (Munich), Ray Douglas (Los Angeles)
17:00 - 17:20	Unilateral, hypothyroid and euthyroid GO - Anja Eckstein (Essen)
17:20 - 17:40	Orbital volumetry and its significance - Wilmar Wiersinga (Amsterdam)
17:40 - 18:00	IgG4-related disease, the inflammatory neophyte in the orbit /lse Mombaerts (Leuven)
18:00 - 18:20	Differential diagnosis of GO: the importance of multidisciplinarity and specialized centers - Lelio Baldeschi (Brussels)
18:20 - 18:40	Diagnostic criteria and management of optic neuropathy - Antonella Boschi (Brussels)
18:45 - 19:05	George von Arx memorial lecture
	Chairperson: Lelio Baldeschi (Brussels)
	The importance of the ophthalmologist and of the joint clinic in GO / Nicole Fichter (Olfen)
19:05 - 20:00	Welcome  Cocktail

 

 

	SCIENTIFIC  PROGRAM Friday, November the 8th, 2019
8:30 - 8:50	Aldo Pinchera memorial lecture
	Chairperson: Paolo Vitti (Pisa)
	Epidemiology and secular trends of GO - Petros Perros (Newcastle upon Tyne)
8:55 - 9:15	Symposium 3: anlmal models of GD and GO
	Chairpersons:  Marian Ludgate (Cardiff),  Gerd Krause (Berlin)
8:55 - 9:15	Epitope peptides derived from the TSH receptor as an effective treatment in a mouse model of Graves' disease and GO - Martin Ungerer (Bavaria)
	The "English" model - Paul Banga (London)
9:35 - 9:55	The "German" model - Utta Berchner-Pfannshmidt (Essen)
10:00 - 11:00	Oral Presentations 2
	Chairpersons: Katharina Ponto (Mainz),  Milos iarkovic (Beigrade)
11:00 - 11:20	Coffee Break
11:20 - 12:40	Symposium 4: ophthalmologlcal controversles and unmet needs
	Chairpersons: Kostas Boboridis (Thessanoliki), Co/in Dayan (Cardiff)
11:20 - 11:40	EUGOGO consensus on eye motility assessment - Nicola Curro (Milan)
11:40 - 12:00	Assessment of primary and secondary outcomes of immunosuppressive treatment of active GO - Luigi Bartalena (Varese)
12:00 - 12:40	DEBATE: ls CAS always a reliable tool to define GO activity?
	Pro: Lucy Clark (Newcastle upon Tyne)
	Cons: Peter Dolman (Vancouver)
12:40 - 14:15	Lunch and  Poster viewing
14:15 - 15:35	Symposium 5: from pathogenesis to medical treatment: focus on the TSH receptor
	Chairpersons: George Kahaly (Mainz),  Terry Smith (Ann Arbour)
14:15 - 14:35	TSH receptor and signaling pathways - Gerd Krause (Berlin)
14:35 - 14:55	TSH receptor and lgF-1 receptor interactions - Marvin Gershengorn (Bethesda)
14:55 - 15.15	Small molecules antagonists as potential new agents for therapeutic targeting of the TSH receptor - Susanne Neumann (Bethesda)
15:15 - 15:35	TSH receptor monoclonal blocking antibodies - Wisia Furmaniak (Cardiff)
15:40 - 16:40	Symposium 6 (Part 1 ): old and novel treatment modalltles
	Chairpersons: Mario Sa/vi (Milan),  Nichole Fichter (O/ten)
15:40 - 16:00	lntravenous glucocorticoids - C/audio Marcocci (Pisa)
16:00 - 16:20	Selenium - Michele Marino (Pisa)
16:20 - 16:40	Mycophenolate (The MINGO Study) - George Kahaly (Mainz)
16:40 - 17:00	Coffee Break
17:00 - 18:35	Symposium 6 (Part 2): Old and novel treatment modallties
	Chairpersons: Simon Pearce (Newcastle upon Tyne), Anja Eckstein (Essen)
17:00 - 17:20	Combined immunosuppression and radiotherapy (The CIRTED study) Peter N. Taylor (Cardiff)
17:20 - 17:40	Teprotumumab - Ray Douglas (Los Angeles)
17:40 - 18:00	Rituximab and other B cell targeting options - Mario Salvi (Milano)
18:00 - 18:20	Tocilizumab - Jose V.  Perez-Moreiras (Santiago de Compostela)
18:20 - 18:50	lnteractive Discussion on Symposium 6
	Chairmen:  Luigi Bartalena (Varese)
18:20 - 18:25	Chairperson's summary
18:25 - 18:50	lnteractive discussion
20:30 - 23:30	Network Dinner
	SCIENTIFIC  PROGRAM Saturday, November the 9th, 2019
8:30 - 9:50	Symposium 7: ophthalmic perspectives
	Chairpersons: Marco Nardi (Pisa),  Peter Dolman (Vancouver)
8:30 - 8:50	Orbital decompression: does the approach matter? A review of the literature - Christoph Hintschich (Munich)
8:50 - 9:10	Outcome measures for strabismus surgery - Branislav Stancovic (Be/grade)
9:10 - 9:30	Treatment of eyelids and tear film alteration in GO - Kostas Boboridis (Thessaloniki)
9:30 - 9:50	Nanotechnology applied to Graves' Orbitopathy: a potential alternative to more invasive medical and surgical treatments - Djon Paridaens (Rotterdam)
9:55 - 10:55	Oral Presentations 3
	Chairpersons: Goksun Ayvaz (Ankara),  Antonella Boschi (Brussels) Coffee  Break
10:55 . 11:15	Coffee  Break
11:15 - 12:05	Patient Forum
	Chairpersons: Dan Morris (Cardiff), Petros Perros (Newcastle upon Tyne)
11:15 - 12:05	The quality of life in GO and the impact of GO in public health - Katharina Ponto (Mainz)
11:35 - 11:55	My life with GO - Janis Hickey (British Thyroid Foundation)
11:55 - 12:15	lmplementing change for improving the care of patients with GO: the TEAMED paradigm - Co/in Dayan (Cardiff)
12:15 - 12:35	Lecture
	Chairperson: Wilmar Wiersinga (Amsterdam)
	Quo vadis GO? - Marius Stan (USA)
12:40 - 1:00	Closing Ceremony